This study is looking at two treatments for neurofibromatosis type 1 (NF1)-associated low-grade glioma (LGG), a type of brain tumor. One treatment is a drug called selumetinib, which stops tumor cells from growing. The other is a standard treatment using two drugs: carboplatin and vincristine, which work to kill or stop the spread of tumor cells. Researchers want to see if selumetinib works as well as, or better than, the standard treatment, especially for improving vision when the tumor affects the optic pathway, which includes the nerves for vision.

• The study involves taking selumetinib at home or receiving carboplatin/vincristine at the hospital over several cycles, with regular MRI check-ups.
• This study requires follow-up visits with exams every few months for several years.
• Participants should be between 2 and 21 years old, with specific health requirements checked before joining.